Skip to main content
Premium Trial:

Request an Annual Quote

Abbott, Alere Agree to Lower Acquisition Price to $5.3B

NEW YORK (GenomeWeb) – Abbott and Alere said today that they have agreed to amend the terms of their acquisition agreement and dismiss lawsuits they had filed against each other.

Under the amended terms, Abbott will pay $51 per share to acquire Alere for a new total price of about  $5.3 billion — reduced from an original purchase price of around $5.8 billion proposed in February 2016 when Abbott announced that it was acquiring Alere.

The transaction is expected to close by the end of the third quarter of 2017. 

After the deal was originally announced, Alere suffered a series of setbacks that prompted Abbott to seek termination of the acquisition. They included the elimination of billing privileges from the Centers for Medicare and Medicaid Services for a substantial Alere division; the permanent recall of an important Alere product platform; a grand jury subpoena from the US Department of Justice over sales practices and dealings in Africa, Asia, and Latin America; and a delay in the filing of Alere's 2015 10-K annual report with the US Securities and Exchange Commission.

In August 2016, Alere filed a complaint in Delaware Chancery Court to compel Abbott to fulfill its obligations under the terms of their merger agreement, and to force its would-be acquirer to act promptly in obtaining antitrust approvals.

Then in November, Abbott sued Alere for breach of contract, claiming that it couldn’t get access to documents promised under the pending merger agreement.

Under the amended acquisition agreement, the firms have set a new date, Sept. 30 this year, by which regulatory approvals must be received.

However, as they move closer to completing the acquisition, Alere has an outstanding piece of business to address. In March, the New York Stock Exchange sent it a notice stating that it is not in compliance with continued listing requirements, because it had failed to file its 2016 annual report 10-K in a timely manner.



The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.